Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 85, Issue 2, Pages 200-204Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2016.02.009
Keywords
Candida; Aspergillus; Antifungal susceptibility; Surveillance
Categories
Funding
- Pfizer
- Astellas Pharma Global Development
- Achaogen
- Actavis
- Actelion
- Allergan
- American Proficiency Institute
- AmpliPhi
- Anacor
- Astellas
- AstraZeneca
- Basilea
- Bayer
- BD
- Cardeas
- Cellceutix
- CEM-102 Pharmaceuticals
- Cempra
- Cerexa
- Cidara
- Cormedix
- Cubist
- Debiopharm
- Dipexium
- Dong Wha
- Durata
- Enteris
- Exela
- Forest Research Institute
- Furiex
- Genentech
- GSK
- Helperby
- ICPD
- Janssen
- Lannett
- Longitude
- Medpace
- Meiji Seika Kasha
- Melinta
- Merck
- Motif
- Nabriva
- Novartis
- Paratek
- Pocared
- PTC Therapeutics
- Rempex
- Roche
- Salvat
- Scynexis
- Seachaid
- Shionogi
- Tetraphase
- Medicines Co.
- Theravance
- ThermoFisher
- VenatoRX
- Vertex
- Wockhardt
- Zavante
Ask authors/readers for more resources
Among 1846 fungal clinical isolates from 31 countries, echinocandin resistance in Candida spp. ranged from 0.0% to 2.8% (highest for anidulafungin versus Candida glabrata), and fluconazole resistance was noted among 11.9% and 11.6% of the C. glabrata and Candida tropicalis, respectively. Two isolates of Aspergillus fumigatus displayed elevated MICs for itraconazole and carried cyp51a mutations encoding TR34 L98H. All Cryptococcus neoformans had azole MIC values below epidemiological cutoff values. The increasing resistance among certain species and more frequent reports of breakthrough infections in patients undergoing antifungal therapy highlights the importance of antifungal surveillance to guide therapy for patients with invasive fungal infections. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available